A share price of Myriad Genetics, Inc [MYGN] is currently trading at $16.17, up 2.93%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MYGN shares have gain 7.80% over the last week, with a monthly amount drifted -26.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on September 19, 2024, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $32. Previously, Wells Fargo started tracking the stock with Overweight rating on August 28, 2024, and set its price target to $35. On June 27, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $29 on the stock. Leerink Partners upgraded its rating to a Outperform and raised its price target to $35 on May 08, 2024. In a note dated December 19, 2023, Wells Fargo initiated an Equal Weight rating and provided a target price of $20 on this stock.
Myriad Genetics, Inc experienced fluctuations in its stock price throughout the past year between $14.72 and $29.30. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $16.17 at the most recent close of the market. An investor can expect a potential return of 79.34% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
Trailing Twelve Months sales for Myriad Genetics, Inc [NASDAQ:MYGN] were 823.60M which represents 11.15% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.25 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.70 points at the first support level, and at 15.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.49, and for the 2nd resistance point, it is at 16.82.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Myriad Genetics, Inc [NASDAQ:MYGN] is 1.90. In addition, the Quick Ratio stands at 1.73 and the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 1.79, the price to book ratio is 2.01.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
